NEXTBio Capital Management LP

Institutional manager·CIK 2038158

Annual return

—

SPY

—

Alpha

—

Invested

$215.4M

Holdings

Trades YTD

Performance · Fund vs SPY

Cumulative return · quarterly snapshots

In development

Quarterly performance not yet computed for this fund.

The metrics pipeline computes return / SPY benchmark / alpha per quarter from this fund's 13F holdings and the SPY adj-close. It hasn't produced enough quarters here yet — the chart fills in automatically once at least two are on record.

Top holdings · current snapshot

Source: 13F-HR

$TERN

TERNS PHARMACEUTICALS INC

Q4 2025: New position (551.2k shares)

14.8%

$PTGX

PROTAGONIST THERAPEUTICS INC

Q4 2025: New position (229.6k shares)

11.2%

$STTK

SHATTUCK LABS INC

Q4 2025: New position (3.15M shares)

9.4%

$VOR

VOR BIOPHARMA INC

Q4 2025: New position (1,000.0k shares)

8.3%

$CMPS

COMPASS PATHWAYS PLC

Q4 2025: New position (752.6k shares)

5.2%

$RYTM

RHYTHM PHARMACEUTICALS INC

Q4 2025: New position (67.6k shares)

5.1%

$XENE

XENON PHARMACEUTICALS INC

Q4 2025: New position (183.7k shares)

4.9%

$PVLA

PALVELLA THERAPEUTICS INC NE

Q4 2025: New position (82.7k shares)

4.8%

$ZBIO

ZENAS BIOPHARMA INC

Q4 2025: New position (322.0k shares)

3.9%

$IVA

INVENTIVA SA

Q4 2025: New position (1.30M shares)

3.4%

See all 24 holdings · Pro →

Recent trades · Last 90 days

No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.

Source data: SEC EDGAR · 13F-HR filings · Last refreshed 08:46 UTC.